Cargando…

Effect of Cladribine on Neuronal Apoptosis: New Insight of In Vitro Study in Multiple Sclerosis Therapy

Background: Cladribine (2-CdA) can cross the blood–brain barrier, resulting in inhibition of DNA synthesis and repair and disruption of cellular proliferation in actively dividing lymphocytes. No data on effect on neurons are available. Aim: To study “in vitro” 2-CdA apoptotic effects on neurons in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruggieri, Maddalena, Gargano, Concetta Domenica, Ferretta, Anna, Manni, Alessia, Capacchione, Antonio, Frigeri, Antonio, Iaffaldano, Pietro, Trojano, Maria, Paolicelli, Damiano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464206/ https://www.ncbi.nlm.nih.gov/pubmed/32823496 http://dx.doi.org/10.3390/brainsci10080548

Ejemplares similares

Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients
por: Paolicelli, Damiano, et al.
Publicado: (2022)

Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method
por: Bollo, Luca, et al.
Publicado: (2021)

Mitochondria, Oxidative Stress, cAMP Signalling and Apoptosis: A Crossroads in Lymphocytes of Multiple Sclerosis, a Possible Role of Nutraceutics
por: Signorile, Anna, et al.
Publicado: (2020)

Gender differences in safety issues during Fingolimod therapy: Evidence from a real‐life Relapsing Multiple Sclerosis cohort
por: Manni, Alessia, et al.
Publicado: (2017)

Lymphocyte Count and Body Mass Index as Biomarkers of Early Treatment Response in a Multiple Sclerosis Dimethyl Fumarate-Treated Cohort
por: Manni, Alessia, et al.
Publicado: (2019)

PBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein Levels
por: De Rasmo, Domenico, et al.
Publicado: (2020)

Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)
por: Patti, Francesco, et al.
Publicado: (2020)

Interdisciplinary approach to opportunistic infections: staphylococcal meningitis in a patient with multiple sclerosis on treatment with dimethyl fumarate
por: Bollo, Luca, et al.
Publicado: (2022)

Magnetoencephalography and High-Density Electroencephalography Study of Acoustic Event Related Potentials in Early Stage of Multiple Sclerosis: A Pilot Study on Cognitive Impairment and Fatigue
por: Paolicelli, Damiano, et al.
Publicado: (2021)

Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years
por: Guerra, Tommaso, et al.
Publicado: (2021)

Impact of depression on the perception of fatigue and information processing speed in a cohort of multiple sclerosis patients
por: Biasi, Madia M., et al.
Publicado: (2023)

A case report of late‐onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review
por: Parisi, Mosè, et al.
Publicado: (2020)

The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy
por: Paolicelli, Damiano, et al.
Publicado: (2016)

Low Serum Urate Levels Are Associated to Female Gender in Multiple Sclerosis Patients
por: Zoccolella, Stefano, et al.
Publicado: (2012)

Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide
por: Bollo, Luca, et al.
Publicado: (2020)

Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
por: Paolicelli, Damiano, et al.
Publicado: (2009)

Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets
por: Gasperini, Claudio, et al.
Publicado: (2010)

Impact of Natalizumab on Cognitive Performances and Fatigue in Relapsing Multiple Sclerosis: A Prospective, Open-Label, Two Years Observational Study
por: Iaffaldano, Pietro, et al.
Publicado: (2012)

Predictors of unemployment status in people with relapsing multiple sclerosis: a single center experience
por: Guerra, Tommaso, et al.
Publicado: (2022)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets
por: Moiola, Lucia, et al.
Publicado: (2022)

Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
por: Savic, Radojka M., et al.
Publicado: (2017)

Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4
por: Centonze, Diego, et al.
Publicado: (2023)

Aquaporin‐1 inhibition reduces metastatic formation in a mouse model of melanoma
por: Simone, Laura, et al.
Publicado: (2017)

Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Potential Diagnostic Biomarkers in Autism Spectrum Disorders: A Preliminary Study
por: Simone, Marta, et al.
Publicado: (2023)

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients
por: Allen-Philbey, Kimberley, et al.
Publicado: (2021)

COVID-19 in Cladribine-treated patient with multiple sclerosis
por: Haham, Nitsan, et al.
Publicado: (2021)

Host-Cell Type Dependent Features of Recombinant Human Aquaporin-4 Orthogonal Arrays of Particles—New Insights for Structural and Functional Studies
por: Pisani, Francesco, et al.
Publicado: (2019)

B and T Immunoregulation: A New Insight of B Regulatory Lymphocytes in Autism Spectrum Disorder
por: De Giacomo, Andrea, et al.
Publicado: (2021)

Aquaporin-4 Autoantibodies in Neuromyelitis Optica: AQP4 Isoform-Dependent Sensitivity and Specificity
por: Pisani, Francesco, et al.
Publicado: (2013)

Current and Emerging Therapies for the Treatment of Multiple Sclerosis: Focus on Cladribine
por: Schreiner, Teri L., et al.
Publicado: (2012)

The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
por: Hermann, Robert, et al.
Publicado: (2018)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Molecular signature associated with cladribine treatment in patients with multiple sclerosis
por: Fissolo, Nicolas, et al.
Publicado: (2023)

Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety
por: Moser, Tobias, et al.
Publicado: (2022)

Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study
por: Petracca, Maria, et al.
Publicado: (2022)

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
por: Warnke, Clemens, et al.
Publicado: (2010)

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine
por: Pakpoor, Julia, et al.
Publicado: (2015)

Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
por: Ceronie, Bryan, et al.
Publicado: (2018)

Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis
por: Afolabi, Dayo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cum8dj0sgfnkdjfuufht0je7jq